CAS Key Laboratory of Cryogenics, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Beijing Key Laboratory of Cryo-Biomedical Engineering, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
ACS Appl Mater Interfaces. 2020 Jun 24;12(25):27984-27993. doi: 10.1021/acsami.0c06023. Epub 2020 Jun 11.
Cryoablation and photothermal therapy are anticancer therapeutic strategies that destroy tumors by external energy intervention of achieving extremely low temperature and very high temperature in a short time. Compared to traditional surgical resection, radiotherapy, and chemotherapy, they have the advantages of being minimally invasive and having less side effects. However, single cryoablation or photothermal therapy itself has limited therapeutic accuracy, which greatly restricts its clinical application. There is still a common phenomenon that the energy transport at the tumor target site cannot be accurately controlled in space and time dimensions, resulting in limited thermal effect and difficulty to form a conformable treatment area, which will result in low targeted killing efficiency, and tumor cells will become residual and undergo metastasis and recurrence. Herein, a multimodal therapy of cryoablation combined with photothermal therapy was proposed. To further enhance the therapeutic performance, a liquid metal hybrid platform, which is composed of a high-thermal-conductivity liquid metal paste and high-photothermal-conversion-efficiency liquid metal nanoparticles, is mediated for cryoablation and photothermal therapy. Cold and heat synergistic effects are realized through this multimodal therapy. Due to the liquid metal hybrid platform, enhanced antitumor efficacy is achieved and . More importantly, the liquid metal hybrid platform-mediated dual therapy is totally noninvasive and does not show obvious systemic toxicity. Collectively, this study has first realized ice (cryoablation)-fire (photothermal therapy) dual noninvasive therapy by one liquid metal platform and demonstrated superior antitumor effect for melanoma treatment. This work explores a new promising multimodal cancer therapy strategy based on the liquid metal platform, which has great potential application in cancer treatment in the future.
冷冻消融和光热治疗是通过外部能量干预实现极低温和极高温度的抗肿瘤治疗策略,在短时间内破坏肿瘤。与传统的手术切除、放疗和化疗相比,它们具有微创和副作用小的优点。然而,单一的冷冻消融或光热治疗本身治疗精度有限,这极大地限制了其临床应用。仍然存在一个普遍的现象,即肿瘤靶区的能量传输在空间和时间维度上无法精确控制,导致热效应有限,难以形成一致的治疗区域,从而导致靶向杀伤效率低下,肿瘤细胞残留并发生转移和复发。在此,提出了冷冻消融联合光热治疗的多模态治疗。为了进一步提高治疗性能,采用了由高热导率液态金属膏和高光热转换效率液态金属纳米粒子组成的液态金属混合平台来介导冷冻消融和光热治疗。通过这种多模态治疗实现了冷-热协同效应。由于液态金属混合平台的存在,实现了增强的抗肿瘤效果和。更重要的是,液态金属混合平台介导的双重治疗完全是非侵入性的,并且没有明显的全身毒性。总之,本研究首次通过一个液态金属平台实现了冰(冷冻消融)-火(光热治疗)双重非侵入性治疗,并展示了对黑色素瘤治疗的优越抗肿瘤效果。这项工作基于液态金属平台探索了一种新的有前途的多模态癌症治疗策略,在未来具有很大的癌症治疗应用潜力。